



FORM 13
(See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER
SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

1. Name of Inspector from whom received : Mrs. Zazokimi, Assistant Drugs Inspector (Food and Drugs)
C.M.O. Office,
Champhai-796321 Mizoram
2. Serial No. and date of Inspector's memorandum : 091/1PA-CPI/II-25, 28-MAY-2025
3. Number of Sample : NIL
4. Date of receipt : 16-JUN-2025
5. Names of drugs purporting to be contained in the sample : Levocetirizine Hydrochloride & Montelukast Sodium Tablets IP (Montura-L)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg. & Exp	Marketed By	Mfg. By
LSD/GUW/2025-GUW/LS/2025-26/0853	26/854	ZT24308B	Jun-2024 May-2026	NA	M/s Zenon Lifesciences Pvt. Ltd., Survey-no. 343/P, Bavla-Sanand Highway, Modasar, Ahmedabad, Gujarat, INDIA 382220.

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector
[the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below
Date of Testing : From 03-Sep-2025 To 10-Oct-2025

COMPOSITION : Each film coated tablet contains:
Levocetirizine Hydrochloride IP 5 mg
Montelukast Sodium IP Eq. to Montelukast 10 mg

Protocol Applied : I.P. 2022

Sr No.	Test Name	Result	Limits
1	Description	White, round, slightly bi-convex, scored on one surface, film coated tablets, in blister pack.	NA
2	Identification	Gives positive test for Levocetirizine Hydrochloride and Montelukast Sodium.	NA
3	Average weight	0.1274 g	NA
4	Dissolution (for Levocetirizine Hydrochloride)	Complies.	NLT 70 % of claim
5	Dissolution (For Montelukast)	Complies.	NLT 70 % of claim

Assay

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Levocetirizine Hydrochloride	5.33 mg/Tablet	5 mg/Tablet	106.6	90 % to 110 %	I.P. 2022
2	Montelukast Sodium eq. to montelukast	10.04 mg/Tablet	10 mg/Tablet	100.4	90 % to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above is of **standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

The sample conform to claim as per I.P. 2022 in respect of test performed.

Date: 06-NOV-2025

GOVERNMENT ANALYST

Rinku Kalita
Government Analyst
R.D.T.L., Guwahati 78

-----END OF REPORT-----

